N-(2-diethylamino-ethyl)-succinamic acid | 72038-39-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(2-diethylamino-ethyl)-succinamic acid
• 英文别名: 4-[2-(Diethylazaniumyl)ethylamino]-4-oxobutanoate
• CAS: 72038-39-2
• 化学式: C₁₀H₂₀N₂O₃
• 分子量: 216.28
• InChiKey: WQSADEBZBOMXSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-diethylamino-ethyl)-succinamic acid 在 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-(2-diethylaminoethyl)succinamic acid chloride
  参考文献：
  名称：

  WO2008/94659

  摘要：

  公开号：
• 作为产物：
  描述：

  丁二酸 、 N,N-二乙基乙二胺 在 1-羟基苯并三唑 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.02h， 生成 N-(2-diethylamino-ethyl)-succinamic acid
  参考文献：
  名称：

  Polarity-Tuning Derivatization-LC-MS Approach for Probing Global Carboxyl-Containing Metabolites in Colorectal Cancer

  摘要：

  含羧基代谢物（CCMs）广泛存在于生物系统中，是生命的基本组成部分。CCMs在生物样本中的全球特征对于理解生理过程和发现相关疾病的发生具有重要意义。然而，由于极性差异巨大、结构多样性、高结构相似性和在质谱中的离子化效率较低，它们的测定面临挑战。在此，我们开发了5-(二异丙基氨基)戊胺（DIAAA）衍生化结合液相色谱-质谱（LC-MS）的方法以绘制CCMs的分布。通过这种方法，灵敏度显著提高。更重要的是，极性CCMs、氨基酸、TCA循环中间体和短链脂肪酸的疏水性显著增强，而低极性CCMs、长链脂肪酸和胆汁酸的亲水性也显著增加，从而实现了卓越的分离效率，使得68种CCMs可以同时测定。此外，极性调节效应被证实是由于DIAAA中脂肪链和氮原子的不同影响所引起的，后者在酸性流动相中以阳离子的形式存在，使用不同的衍生化试剂。最后，该衍生化方法被用于寻找结直肠癌（CRC）患者的潜在生物标志物，识别出52种与多条关键代谢通路（包括氨基酸代谢、TCA循环、脂肪酸代谢、丙酮酸代谢和肠道菌群代谢）相关的CCMs。这种创新的极性调节衍生化-LC-MS方法被证明是探测各种生物样本全球代谢组的高分离效率和灵敏度的有价值工具。

  DOI：

  10.1021/acs.analchem.8b01873

文献信息

• A pharmaceutical composition for use in treating an ocular disease or condition and a method for producing the composition
  申请人：Allergan, Inc.

  公开号：EP2425816A2

  公开（公告）日：2012-03-07

  The present invention provides a pharmaceutical composition for use in treating an ocular disease or condition, the composition comprising: a chitosan composition comprising a treated chitosan, a modified chitosan, a modified and treated chitosan or a mixture thereof, each modified and/or treated chitosan exhibiting a different chemical, physical and/or performance property or characteristic relative to the corresponding unmodified/untreated chitosan, and a therapeutic agent selected from a corticosteroid and a mixture of corticosteroids; wherein: each treated chitosan is obtained by dialyzing chitosan against water and a salt and/or anionic solution, and each modified chitosan is obtained by one or more of covalent attachment of one or more functional groups to chitosan, non-covalent association of one or more atomic or molecular agents with chitosan and coaddition of one or more atomic or molecular agents with chitosan, the therapeutic agent is covalently bonded to at least one treated and/or modified chitosan directly or via a linker, and the chitosan composition is adapted to release a therapeutically effective amount of the therapeutic agent over a period of time. A process for manufacturing the pharmaceutical composition is also provided, the process comprising contacting the above chitosan composition with a therapeutically-effective amount of the above therapeutic agent under conditions such that the therapeutic agent is covalently bonded to at least one treated and/or modified chitosan.

  本发明提供了一种用于治疗眼部疾病或病症的药物组合物，该组合物包括 壳聚糖组合物，包括经处理的壳聚糖、经改性的壳聚糖、经改性和处理的壳聚糖或其混合物，相对于相应的未改性/未处理的壳聚糖，每种经改性和/或处理的壳聚糖表现出不同的化学、物理和/或性能特性，以及 选自皮质类固醇和皮质类固醇混合物的治疗剂； 其中 每种处理过的壳聚糖是通过将壳聚糖与水和盐及/或阴离子溶液透析而获得的，每种改性壳聚糖是通过将一种或多种官能团共价连接到壳聚糖、一种或多种原子或分子剂与壳聚糖的非共价结合以及一种或多种原子或分子剂与壳聚糖的共添加而获得的、 治疗剂直接或通过连接体与至少一种经处理和/或修饰的壳聚糖共价键合，以及 壳聚糖组合物能够在一段时间内释放治疗有效量的治疗剂。 还提供了一种制造药物组合物的工艺，该工艺包括在使治疗剂与至少一种经处理和/或修饰的壳聚糖共价键合的条件下，将上述壳聚糖组合物与治疗有效量的上述治疗剂接触。
• NOVEL BIOMATERIALS FOR OCULAR DRUG DELIVERY AND A METHOD FOR MAKING AND USING SAME
  申请人：ALLERGAN, INC.

  公开号：EP2114370A2

  公开（公告）日：2009-11-11
• NOVEL BIOMATERIALS AND A METHOD FOR MAKING AND USING SAME
  申请人：Utecht Ronald E.

  公开号：US20080200948A1

  公开（公告）日：2008-08-21

  Novel biomaterials are disclosed having unique properties that make it a useful material in adhesives, local drug delivery applications and as filler or bulking material. The biomaterials are strong, safe and easily used as a surgical adhesive. Treated chitosan, modified chitosan or modified and treated chitosan compositions are disclosed displaying strengths suitable for general surgical applications. The materials can be used as a drug delivery vehicle which allows for the localization of the delivered drug as well as a programmable tether which allows for the release of the drug on a timed basis or in response to a physiological state such as the release of proteolytic enzymes. The materials of this invention can also be modified and treated to optimize the retention of water, thereby serving as a useful filler or bulking material.
• US8252771B2
  申请人：——

  公开号：US8252771B2

  公开（公告）日：2012-08-28
• US9855337B2
  申请人：——

  公开号：US9855337B2

  公开（公告）日：2018-01-02